Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger, Inc. (Nasdaq: SDGR) has granted stock options for 101,715 shares to 30 newly hired employees as an incentive for their employment acceptance. The options were issued under the company’s 2021 Inducement Equity Incentive Plan with an exercise price of $29.82, equal to the closing stock price on April 15, 2022. The vesting period is structured, with U.S. employees vesting monthly over four years, while employees in India and Japan will vest annually over three years. This move aims to enhance talent acquisition and retention as Schrödinger continues to innovate in drug discovery.

Schrödinger, Inc. (Nasdaq: SDGR) presented promising preclinical data on its Wee1 inhibitors at the AACR Annual Meeting. These inhibitors demonstrate strong anti-tumor activity and potential for monotherapy and combination therapy. The company plans to identify a Wee1 development candidate by 2022 and submit an IND application to the FDA in 2023. The study highlighted a compound, STC-8123, showing high selectivity and sustained anti-tumor effects without significant side effects, indicating a favorable dosing regimen.

Schrödinger, Inc. (Nasdaq: SDGR) announced the granting of non-statutory stock options for 42,425 shares to 17 new employees on March 15, 2022. This grant, part of the 2021 Inducement Equity Incentive Plan, serves as an inducement for employment acceptance, compliant with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $28.81 per share, equal to the closing price on the grant date. Options vest over four years, with different vesting schedules for U.S. and India-based hires.

Schrödinger is focused on enhancing drug discovery through its physics-based software platform.

Schrödinger, Inc. (Nasdaq: SDGR) announced promising preclinical data on its small-molecule Wee1 inhibitors, to be presented at the AACR Annual Meeting in New Orleans (April 8-13, 2022). These inhibitors may induce apoptosis in tumor cells by triggering DNA damage. Early studies show significant anti-tumor activity in ovarian and uterine cancers. Schrödinger plans to select a development candidate later this year, with an emphasis on strong pharmacodynamics and potential use as monotherapy or in combination therapy.

Schrödinger (Nasdaq: SDGR) announced its participation in the Truist Securities Life Sciences AI Symposium on March 1, 2022. Karen Akinsanya, Ph.D., will join a panel discussing technology-enabled drug discovery at 10:10 a.m. ET. An on-demand workshop titled “Transforming Molecular Design of Novel Drug,” hosted by Ramy Farid, Ph.D., will also be available. Access details for the panel and workshop can be found in the investors section of Schrödinger's website. Founded in 1990, Schrödinger employs over 650 individuals and focuses on innovative drug discovery through its physics-based software platform.

Schrödinger, Inc. (Nasdaq: SDGR) reported a strong fourth quarter with software revenue of $38.6 million, a 55% increase from Q4 2020. For the full year 2021, total revenue reached $137.9 million, up 28% year-over-year, with software revenue of $113.2 million, increasing 22%. The company provided a positive outlook for 2022, anticipating total revenue between $161 million and $181 million, and software revenue between $126 million and $136 million. Additionally, Schrödinger announced strategic goals including a Phase 1 clinical study of its MALT1 inhibitor.

Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options totaling 32,425 shares to 17 newly hired employees as part of its 2021 Inducement Equity Incentive Plan on February 14, 2022. These options, which have an exercise price of $26.99 per share, will vest over four years. The grants aim to attract talent, complying with Nasdaq Listing Rule 5635(c)(4). Schrödinger leverages its physics-based software platform for drug discovery and materials development, engaging with clients across over 70 countries.

Schrödinger (Nasdaq: SDGR) will release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. A conference call will take place at 4:30 p.m. ET. Interested parties can access the live webcast on Schrödinger’s website. The company focuses on a physics-based software platform that enhances therapeutic and materials discovery, used by various organizations globally. With over 500 employees and clients in more than 70 countries, Schrödinger aims to lower costs and speed up drug development.

Schrödinger (Nasdaq: SDGR) will present a company overview at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 16, 2022, at 1:00 p.m. ET. The live presentation will be accessible via the company's website under the 'News & Events' section and will be archived for about seven days.

Founded in 1990, Schrödinger's software platform accelerates drug and materials discovery, engaging with over 500 employees and customers in over 70 countries.